Rythmol SR

Rythmol SR is a prescription medication used to treat irregular heartbeat (known medically as arrhythmia). This medication belongs to a group of drugs called Class IC antiarrhythmics which work by blocking sodium channels in the heart, slowing down electrical signals to stabilize heart rhythm.

Rythmol SR comes in an extended-release capsule form and usually taken twice daily, once every 12 hours.

Common side effects include nausea, vomiting, and unusual taste. Rythmol SR can cause dizziness. Do not drive or operate heavy machinery until you know how it affects you.

Rythmol SR is a prescription medication used to treat life-threatening, ventricular arrhythmias (irregular heartbeats). Rythmol SR is also used to correct abnormal heart rate in patients with:

• paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease.
• paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease.

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

• Glaxo SmithKline Pharmaceuticals

Common side effects include:

• unusual taste
• nausea
• vomiting
• dizziness
• constipation
• headache
• fatigue
• blurred vision

This is not a complete list of Rythmol SR side effects. Ask your doctor or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

WARNING: MORTALITY

In the National Heart, Lung and Blood Institute’s Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than 6 days but less than 2 years previously, an increased rate of death or reversed cardiac arrest rate (7.7%; 56/730) was seen in patients treated with encainide or flecainide (Class IC antiarrhythmics) compared with that seen in patients assigned to placebo (3.0%; 22/725). The average duration of treatment with encainide or flecainide in this study was 10 months.

The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening ventricular arrhythmias, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.